These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 27137144)
1. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144 [TBL] [Abstract][Full Text] [Related]
2. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants. Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832 [TBL] [Abstract][Full Text] [Related]
3. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217 [TBL] [Abstract][Full Text] [Related]
4. Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. Narasimhan NI; Dorer DJ; Niland K; Haluska F; Sonnichsen D J Clin Pharmacol; 2013 Sep; 53(9):974-81. PubMed ID: 23801357 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers. Shaik MN; Hee B; Wei H; LaBadie RR Br J Clin Pharmacol; 2018 Jun; 84(6):1346-1353. PubMed ID: 29488303 [TBL] [Abstract][Full Text] [Related]
6. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. Abbas R; Boni J; Sonnichsen D Drug Metab Pers Ther; 2015 Mar; 30(1):57-63. PubMed ID: 25803093 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers. Wang H; Yang Y; Chen Z; Fu L; Yu M; Jiang L; Wang C; Men L; Minto I; Yang D; Zhai Y Clin Transl Sci; 2024 Sep; 17(9):e70021. PubMed ID: 39228016 [TBL] [Abstract][Full Text] [Related]
8. Effects of food on the pharmacokinetics of ponatinib in healthy subjects. Narasimhan NI; Dorer DJ; Niland K; Haluska F; Sonnichsen D J Clin Pharm Ther; 2013 Dec; 38(6):440-4. PubMed ID: 23888935 [TBL] [Abstract][Full Text] [Related]
9. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. Prakash C; Fan B; Ke A; Le K; Yang H Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634 [TBL] [Abstract][Full Text] [Related]
10. Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin. Bernard A; Vaccaro N; Acharya M; Jiao J; Monbaliu J; De Vries R; Stieltjes H; Yu M; Tran N; Chien C Clin Pharmacol Drug Dev; 2015 Jan; 4(1):63-73. PubMed ID: 27128004 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects. Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D Clin Drug Investig; 2014 Oct; 34(10):723-9. PubMed ID: 25145453 [TBL] [Abstract][Full Text] [Related]
12. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236 [TBL] [Abstract][Full Text] [Related]
13. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Vishwanathan K; Dickinson PA; So K; Thomas K; Chen YM; De Castro Carpeño J; Dingemans AC; Kim HR; Kim JH; Krebs MG; Chih-Hsin Yang J; Bui K; Weilert D; Harvey RD Br J Clin Pharmacol; 2018 Jun; 84(6):1156-1169. PubMed ID: 29381826 [TBL] [Abstract][Full Text] [Related]
14. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects. Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758 [TBL] [Abstract][Full Text] [Related]
15. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects. Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634 [TBL] [Abstract][Full Text] [Related]
16. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects. Barbour AM; Punwani N; Epstein N; Landman R; Cimino E; Yuska B; Wang P; He K; Chen X; Yeleswaram S J Clin Pharmacol; 2019 Dec; 59(12):1641-1647. PubMed ID: 31282592 [TBL] [Abstract][Full Text] [Related]
17. Effects of Quinidine or Rifampin Co-administration on the Single-Dose Pharmacokinetics and Safety of Rilzabrutinib (PRN1008) in Healthy Participants. Rask-Madsen C; Katragadda S; Li M; Ucpinar S; Chinn L; Arora P; Smith P Clin Pharmacol Drug Dev; 2024 Jun; 13(6):590-600. PubMed ID: 38623935 [TBL] [Abstract][Full Text] [Related]
18. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator. Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115 [TBL] [Abstract][Full Text] [Related]
19. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720 [TBL] [Abstract][Full Text] [Related]
20. The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans. Barve A; Kovacs SJ; Ke J; Crabbe R; Grosgurin P; Menetrey A; Nicolas-Métral V; Dabovic K; Dole K; Zhang J; Praestgaard J; Sunkara G; Stein D Clin Pharmacol Drug Dev; 2015 Jan; 4(1):25-32. PubMed ID: 27128001 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]